Ann: Sigma 2017/2018 Full Year ASX Release, page-2

Really surprises me that we aren't given a useful presentation. They really need to give us comparable (to pcp) underlying metrics for the business excluding their biggest customer and excluding the Hep B. If you haven't calculated this, revenue was down 3.5%.
Also we don't get pharmacy comp sales, and I didn't see the Non PBS %.

Also they are presenting us with a trust us number with restructuring and dual op costs mixed together. They are both different types of costs IMO.

My assumption is always that if the presentation is deliberately opaque, then the business is doing badly - and obviously it is. Inventory turns are lower too, which is poor.

Also why hire an expensive investment banker to help you find M+A opportunities. How can they match the expertise that sigma has actually running such a business?

I think it is time to demand meaningful metrics from the management - but then again I wouldn't hold this stock anyway - so up to shareholders - lol.

Nuff said